Table 3.
Subject | Efficacy index | Effect value | 95% CI |
---|---|---|---|
Common pneumonia | Flu-like symptoms | WMD = −1.81 | −2.17, −1.47 |
Sputum | WMD = −1.10 | −1.94, −0.52 | |
Pulmonary rales | WMD = −2.03 | −2.87, −1.21 | |
Pulmonary imaging improvement | WMD = −1.88 | −2.45, −1.37 | |
Curative effect | OR = 3.65 | 2.69, 5.13 | |
Healing period | WMD-1.68 | −2.80, −0.53 | |
Adverse reaction | OR = 0.75 | 0.50, 1.19 | |
| |||
COVID1-19 pneumonia | Flu-like symptoms | OR = 3.18 | 2.18, 4.63 |
Sputum∗ | OR = 4.30 | 0.36, 47.40 | |
Shortness of breath | OR = 10.62 | 2.80, 66.79 | |
Breathlessness | OR = 4.81 | 0.29.42.01 | |
Chest tightness∗ | OR = 3.02 | 0.77, 28.11 | |
Pulmonary imaging improvement∗ | OR = 1.77 | 0.95, 3.41 | |
Curative effect | OR = 2.49 | 1.58, 4.85 | |
Healing period | WMD = −2.06 | −4.01, 0.01 | |
Conversion of severe cases | OR = 0.46 | 0.10, 0.92 | |
| |||
All | Adverse reactions∗ | OR = 0.74 | 0.54, 1.05 |
∗The sensitivity analysis results indicated that deleting individual studies would change the combined results of the meta-analysis.